Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1 - Full Text View

Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) New York University School of Medicine
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00067158

Purpose

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Condition	Intervention	Phase
Tobacco Use Disorder	Drug: nicotine transdermal system	Phase III

MedlinePlus related topics:

Quitting Smoking Smoking

Drug Information available for:

Nicotine polacrilex Nicotine tartrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Smoking Cessation

Estimated Enrollment:	585
Study Start Date:	April 2003
Study Completion Date:	July 2004
Primary Completion Date:	July 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

Patient is psychotic
Use of smokeless tobacco
Use of other smoking cessasation product
Pregnancy
Patient has hyper-tension, heart problems, or skin condition

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067158

Locations


United States, California
	Matrix Institute on Addictions
	Los Angeles, California, United States, 90016
	Tarzana Treatment Center
	Tarzana, California, United States, 91356

United States, Florida
	Center for Drug Free Living
	Orlando, Florida, United States, 32805
	SPECTRUM
	Miami, Florida, United States, 33156

United States, Michigan
	Chelsea Arbor Addictions Treatment Center
	Ann Arbor, Michigan, United States, 48103
	Psychiatry and Behavioral Medicine Professionals I
	Detroit, Michigan, United States, 48207

United States, New York
	Mount Sinai Medical Center
	New York, New York, United States, 10029
	Narco Freedom (Bridge Plaza)
	Long Island City, New York, United States, 11101
	St. Luke's Roosevelt Hospital Center
	New York, New York, United States, 10019
	St. Luke's Roosevelt Hospital Center, Womens
	New York, New York, United States, 10025

United States, North Carolina
	Coastal Horizons Center, Inc.
	Wilmington, North Carolina, United States, 28412
	Piedmont Behavioral Healthcare
	Concord, North Carolina, United States, 28001

United States, South Carolina
	Behavioral Health Services of Pickens County
	Pickens, South Carolina, United States, 29671

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York University School of Medicine

Investigators


Principal Investigator:	Malcolm Reid, Ph.D.	New York University School of Medicine

More Information

Data Elements This link exits the ClinicalTrials.gov site

Study ID Numbers:	NIDA-CTN-0009-1
First Received:	August 12, 2003
Last Updated:	July 28, 2008
ClinicalTrials.gov Identifier:	NCT00067158
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Nicotine polacrilex

Smoking

Nicotine

Mental Disorders

Tobacco Use Disorder

Substance-Related Disorders

Disorders of Environmental Origin

Additional relevant MeSH terms:

Neurotransmitter Agents

Cholinergic Agonists

Molecular Mechanisms of Pharmacological Action

Nicotinic Agonists

Physiological Effects of Drugs

Central Nervous System Stimulants

Cholinergic Agents

Pharmacologic Actions

Autonomic Agents

Therapeutic Uses

Ganglionic Stimulants

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2008